PDCD1 and melanoma: To characterize resistance to PD-1 checkpoint blockade, Manguso et al. applied CRISPR-gene editing to tumors in mice treated with immunotherapy to discover immunotherapy targets, specifically testing over 2000 genes expressed by melanoma cells to identify those that synergize with or cause resistance to checkpoint blockade [29].